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Abstract 
A 54 years old man was admitted to our hospital due to progressive signs and symptoms of Cushing 
syndrome. Once a biochemical diagnosis of Adrenocorticotropic Hormone (ACTH)-dependent 
hypercortisolism was established, high dose 8 mg overnight Dexamethasone Suppression Test (HDDST), 1-
deamino-8-D-arginine vasopressin (DDAVP) stimulation test and a Magnetic Resonance Imaging (MRI) 
led to conflicting results and an ectopic ACTH syndrome was diagnosed following a Bilateral Inferior 
Petrosal Sinus Sampling (BIPPS).The localization of the source of ectopic ACTH secretion turned out to be 
a challenging task because most of imaging exams gave a negative result. After a prolonged follow-up, a 
chest Computed Tomography (CT) scan gave a morphological confirmation of a small focus in the right 
lung previously detected by a 
68
Gallium-DOTATOC- Positron Emission Tomography (PET). A right lower 
lobectomy of the lung was performed and an ACTH-positive typical pulmonary carcinoid was diagnosed. 
Before surgery, a good management of hypercortisolism was obtained with somatostatin analog lanreotide 
for years, and only after a likely escape phenomenon was successfully prescribedoff-labelpasireotide. In 
this patient with occult ectopic ACTH syndrome (EAS),a watchful waiting approach, based on imaging re-
evaluation,representeda valuable option, provided that a good management of hypercortisolism and its end-
organ complications wasobtained. 
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Introduction 
The evaluation of hypercortisolism may be difficult due to the lack of specific signs and symptoms 
and tothe need to excludea pseudo-Cushing syndrome by multiple laboratory tests [1].The EAS is 
considered among the most challenging endocrine diseases [2-3] because of pitfallsin both 
diagnostic and therapeutic options [2, 3-5].The localization of an occult tumor with imaging 
techniques is often difficultand about 20% of ectopic ACTH-secreting tumorsare not localized[4, 
6-7].Overexpression of somatostatin receptors inNeuroEndocrine Tumors (NETs) cells and in 
many ectopic ACTH secreting tumors has important implications for imaging and therapeutic 
options[8].When a clearevidence is not available by imaging,Cushing's comorbidities management 
anda long-term follow-up is mandatory[2, 4-7, 9]. 
 
APMB - Atti della Accademia Peloritana dei Pericolanti 
Classe di Scienze Medico Biologiche 
Vol. 106(2) 2018 
 
ISSN 1828-6550 
 
 
DOI: 10.6092 / 1828-6550 / APMB.106.2.2018.A2 
 
Atti della Accademia Peloritana dei Pericolanti Classe di Scienze Medico-Biologiche  (2018) ,106:A2(1-8) 
DOI:10.1478 / APMB.106.2.2018.A2. 
Case Report 
A 54 years old man was admitted to our hospital with long-standing signs and symptoms of 
Cushing syndrome.His previous medical history was characterized by a weight gain of 
approximately 20 kg in the last years, a five-years hypertension and dyslipidemia that have been 
treated with irbesartan, amlodipine and a statin. During a previoushospitalization for the evaluation 
of a peptic ulcer, he was diagnosed with multiple painless rib fractures and moderate bilateral 
adrenal hyperplasiaonCTscan, whilelaboratory tests revealed the presence of lymphocytopenia and 
potassium 3.5 mEq/L. He complained fatigue combined with easy bruising, poor skin healing and 
muscle weakness and he showed a facial plethora at physical examination.Once the patient was 
admitted to our hospital, endocrinological laboratory evaluation [Table 1] revealed elevated 24 
hours urinary free cortisol (24hCLU) levels (760 µg/24 h), absence of suppression of serum 
cortisol at Low dose 1 mg overnight Dexamethasone Suppression Test (LDDST) and elevated 
midnight serum cortisol levels, sothe diagnosis of Cushing syndrome was confirmed. Asubsequent 
evaluation,showed ACTH levels (240 pg/ml) consistent with an ACTH-dependent cause of 
Cushing Syndrome. Concerning HDDST,a >50% cortisol suppression was observed and the 
gadolinium-enhanced pituitary MRI revealed no abnormalities. Chromogranin A (CgA) was 
normal and other hormonal abnormalities were excluded [Table 4]. Because of the inconclusive 
result of the previous tests, the patient was sent to an experienced referral center (San Raffaele 
Hospital, Milano) to perform a BIPSS. During the hospitalization,the patient underwentDDAVP 
stimulation test,which showed a positive ACTH and cortisol response [Table 2a]; BIPSS with 
Corticotropin Releasing Hormone (CRH) stimulation showed an ACTH petrosal sinus/peripheral 
ratio consistent with an ectopic cause of the ACTH secretion [Table 2b]. An acute octreotide 
challenge test (OctCT) was performed and showed a good response [Table 3]. Chest and abdomen 
CT were negative and the somatostatin receptor scintigraphy with indium 111-pentetreotide 
(Octreoscan, OCT) did notdisplayany pathological uptake.Due to the biochemical and imaging 
studies suggestingan occult Ectopic ACTH Syndrome and the lackof  life-threatening 
hypercortisolism in the short term,the disease was managed by medical therapy and a watchful 
waiting approach was adopted. During the follow-up,imaging techniques were repeatedregularly 
[Table 1]. Three68Gallium-DOTATOC-PETs were performed in the following years and they 
always showed a small area in the right lung,which was not confirmed by CT scan. Another 
gadolinium-enhanced MRI of the pituitary revealed no abnormalities. The absence of a 
morphological confirmationof the lesion by CT scan, prevented a surgical approach until the last 
CT identified a focal lesion in the right lung concordant with the focus showed by 68Gallium-
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DOTATOC-PETs. 
 
Table 1. First/second level diagnostic evaluation and imaging investigation. I and II level diagnostic tests were performed 
between november 2008 (Garibaldi Nesima hospital, Catania) and march 2009 (S. Raffaele hospital, Milano). 
 Year Results Notes 
C count 2008 
2009 
WBC 13900/mL; LY 9.5%; NE 
84% 
WBC 16400/mL; LY 19.4%; NE 
74.6% 
 
Potassium 2008 
2009 
4.6 mEq/L 
3.8 mEq/L 
 
I level    
24hCLU 2008 760 µg/24h (RV 32-243)  
LDDST 2008 36.3 µg/dL Administration of 1 mg of dexametasone at 12 
pm followed by cortisol measurement at 8 am  
AMC 2008 23.7 and 20.1 µg/dL Two cortisol determinations at 11 and 12 pm 
respectively 
II level    
ACTH 2008 240 pg/mL (RV <60)  
HDDST 2008 Cortisol suppression 51.84% Basal cortisol: 24.5 µg/dL 
Post-suppression test cortisol: 11.8 µg/dL 
CRHST \ \ Not Available 
Pituitary MRI 2008 Negative  
DDAVPStimulation 
Test 
2009 ACTH increment 227% 
Cortisol increment 69% 
See table 2a for details 
BIPSS with CRH 
stimulation 
2009 ACTH ratio < 2 (basal) 
ACTH ratio < 3 (after CRH 
stimulation) 
See table 2b for details 
OctCT 2009 ACTH suppression after 4 h: 
89.5% 
Cortisol suppression after 4 h: 
63.4% 
See table 3 for details 
CgA 
NSE 
Calcitonin 
2008 
2009 
2009 
46 ng/mL (RV <101.9) 
21.6 µg/L (RV 0-12.5) 
2 pg/mL (RV 1-12) 
 
Imaging    
Total body CT 2008 Negative  
OCT 2009 Negative  
Total body CT 2010 Negative  
PET 2010 Small focus  in the right lung  
   Computed tomographies performed between 
2010-2014 are not currently available.  
They always showed a negative result 
PET 2014 Small focus  in the right lung  
Pituitary MRI 2014 Negative  
Total body CT 2015 Negative  
PET 2017 Moderate focus  in the right lung  
Total body CT 2017 Focal lesion in the right lung  
AMC: Awake Midnight serum Cortisol, CRHST: CRH Stimulation Test, LY: Lymphocytes,  NE: Neutrophils, NSE: Neuron Specific Enolase, RV: 
Reference Values, WBC: White Blood Cells 
 
Table 2a. DDAVPStimulation Test. ACTH (pg/ml) and cortisol (µg/dL) measurement before and after 
administration of 1-deamino-8-D-arginine vasopressin. Information about desmopressin dosage is unavailable. 
 ACTH (pg/mL) ACTH rise (%) Cortisol (µg/dL) Cortisol rise (%) 
Basal 44  26.4  
15' 144 227% 38.0  
30' 144  43.3  
45' 119  44.5  
60' 97  44.7 69% 
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Table 2b. BIPSSwith CRH stimulation. ACTH measurement (pg/ml) before and after administration of 100 µg CRH 
iv. Information about the ovine or human nature of CRH is not available. 
 Peripheral venous 
blood 
Right inferior 
petrosal sinus 
venous blood 
Right 
PS/peripheral ratio 
Left inferior 
petrosal sinus 
venous blood 
Left 
PS/peripheral 
ratio 
Basal 33 40 1.21 34 1.03 
2' 32 51 1.59 40 1.25 
5' 36 50 1.39 42 1.17 
10' 36 50 1.39 46 1.28 
15' 35 \ \ 45 1.29 
PS: Petrosal Sinus 
 
Table 3. Octreotide Challenge Test: determination of ACTH and cortisol before and after administration of Octreotide, 1 mg sc 
 ACTH (pg/ml) Cortisol (µg/dL) 
Basal 57 290 
60' 14 196 
120' 11 169 
180' 13 147 
240' 6 106 
 
 
Table 4. Hormonal evaluation 
 2008 RV 
TSH 0.55 µU/mL 0.35-4.94 
FT3 2.0 pg/mL 1.71-3.71 
FT4 0.87 ng/dL 0.7-1.48 
FSH 4.11 mIU/mL 1.37-13.58 
LH 2.1 mIU/mL 0.57-12-07 
Testosterone 4.4 ng/mL 1.42-9.23 
Prolactin 22.14 ng/mL 2.58-18.12 
PTH 
Calcium 
Phosphorus 
43.1 pg/mL 
9.7 mg/dL 
2.8 mg/dL 
15-68 
8.4-10.2 
2.3-4.7 
FSH: Follicle Stimulating Hormone, FT3: Free Triiodothyronine, FT4: Free Thyroxine, LH: Luteinizing Hormone, PTH: Parathyroid Hormone, 
TSH: Thyroid Stimulating Hormone 
 
A right lower lobectomy of the lung was therefore performed and,onhistopathological 
examination, an ACTH-positive typical pulmonary carcinoid was diagnosed [Table 5]. Post-
operative laboratory evaluation revealed remission of hypercortisolism and cortone acetate 
was prescribed to manage a glucocorticoid withdrawal syndrome (37.5 mg daily).During the 
prolongedfollow-up before surgery, hypercortisolism was managed with a medical approach 
[Table 6].  The first drug prescribedwas ketoconazole (400 mg/die), even if it was 
discontinued few months later, due to the need to perform dynamic tests. Considering the 
responsiveness to a somatostatin analog with the octreotide challenge test, the patient was 
therefore treated with lanreotide at an initial dose of 60 mg im/28 days with clinical and 
biochemical normalization of cushingoid features. 24-h urinary free cortisol and ACTH 
levelswere around the normal range and a satisfying Cushing's features management during 
the follow up was obtained. During the subsequent follow-up,lanreotide dose was increased 
to 90 mg/28 days and later to 120 mg/28 days untilalaboratory evaluation revealed elevated 
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24-h urinary free cortisol levels (309 and 348 mcg/24 h) andlanreotide was therefore 
discontinued.Then, the patient was treated with pasireotide 0,6 mg sc twice daily off-
label,obtaining the normalization of 24-h urinary free cortisol levels in two months. 
Table 5. Histopathological examination of the ACTH-secreting tumor 
Diagnosis Typical ACTH-secreting carcinoid 
Size 7 mm 
Proliferation index (Ki67) 2-3% 
Mitotic index 0x10HPF 
Immunophenotype Synaptophysin (+), CgA (+), ACTH (+), CKpool (+), TTF1 (-), S100 (-), SOX10 (-), 
GATA3 (-), MelanA (-) 
HPF: High Power Fields 
 
Table 6. Main therapeutic steps. 24hCLU before and after therapeutic modifications are reported. 
Therapy Posology Year of 
prescription 
24hCLU (µg/24h) 
RV 10-110 
Notes 
Ketoconazole  400 mg/die November 
2008 
 
\ 
Discontinued 2 weeks 
before performing  march 
2009 hormonal evaluation 
Lanreotide   Before After  
60 mg im/28 
days 
April 2009 \ \ 
90 mg im/28 
days 
September 
2010 
 
\ 
2013: 75 
2013: 69 
2014: 10 
2014: 13 
120 mg im/28 
days 
June 2015 379 2010: 76 
2010: 72 
Pasireotide  
0.6 mg sc 
twice/daily 
 
January 2017 
Before After Discontinued in june 
2017, before performing 
right lower lobectomy of 
the lung. 
The patient showed a poor 
biochemical control of 
hypercortisolism in the 
last month before 
discontinuation. 
309 
348 
76 
45.5 
Surgery  June 2017   Right lower lobectomy of 
the lung 
 
 
Discussion 
Our patient showed most of features that specifically characterize Cushing's syndrome (easy 
bruising, facial plethora, proximal muscle weakness[1]), and the first diagnostic steps were quite 
straightforward witha diagnosis of ACTH-dependent hypercortisolism. Although overlapping 
values are often observedbetween Cushing disease and ectopic ACTH syndrome [4-5],elevated 
ACTH levels suggested an ectopic ACTH-dependent hypercortisolism. HDDST and DDAVP 
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Stimulation Test, performed as second line diagnostic evaluation,suggested a Cushing Disease. 
Most ectopic ACTH-secreting tumors responsive to HDDST are pulmonary carcinoids [4-6], and 
since MRI was negative, BIPSS was performed as gold standard technique to rule out the 
possibility of a Cushing Disease[3,4-5]. Despite BIPSSis characterized by high sensibility and 
specificity, >95% in most series [3,7], it is interesting to note that false positives have been 
reported in ACTH secreting bronchial carcinoids [5].A CRH Stimulation Test was not performed 
because not available at that time. However, in the case oftwo dynamic testssuggesting a pituitary 
ACTH-secreting adenoma and a negative MRIa BIPSS should have been performed to 
discriminate the source of the ACTH secretion.Once a biochemical diagnosis of EASis given,the 
diagnostic challenge is the localization of the ACTH-secreting tumor, followed by its surgical 
removal(as first-line option)[9].According to the currentliterature,approximately50% of ACTH 
secreting tumors are detected at the initial investigations ("overt"), 20% arenot ("occult") and 30% 
are localized at thesubsequent follow-up ("covert") [6-7]. In our patient,we were not able to 
localize the tumor for several years, even withthe useofmultiple imaging techniques and a long-
term follow-up; only 9 years after the initial biochemical diagnosis of EAS, a typical pulmonary 
carcinoid was diagnosed (making our case a challenging "covert" EAS).  
Most tumours underlyingectopic Cushing syndromearelocalized in the lung [6] and CT 
isconsidered the "most useful first examination", with a sensitivity  >98% in overt cases. MRI, 
OCT, and PET are alsouseful imaging techniquesto confirm a previousimaging or to localize a still 
occult tumor. 68Gallium-SSTR (Somatostatin Receptor)-PET shows the greatest sensitivity in 
localizing covert cases, so it is considered a very useful second/third level examination and the 
best follow-up imaging technique[7]with an high impact on NETs clinical decision-making [11-
12]. 
In our patient a CT total body and an OCT were performed as first-line examinations, while CT 
and 68Gallium-DOTATOC-PETrepresented the corner stone of the follow-up. 
Since all available diagnostic techniquesmay provideboth false-positive and negative results, a 
double step approach is suitable. In this view, surgery may be performed only when bothfirst and 
second line exam are able to detect and localize tumor mass [7].In particular, the diagnosis of 
pulmonary carcinoids ischallenging because they are often small (average 1 cm) and, therefore, 
difficult to detect and localize [2,5-6]. 
While PET imaging has been described as "additive and synergistic to CT imaging" [10], CT imaging is 
mandatory in the diagnosis of NETs as underlined in the last Neuroendocrine tumors guidelines. 
Regarding PET imaging, four recent meta-analyses showed that 68Gallium-SSTR-PET hasaspecificity 
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ranging 88-95% [8, 11-14]. 
The choice of a watchful waiting approach instead of surgery was carefully evaluatedalong with 
thesurgeon. Giventhe good controlof hypercortisolism by medical therapy, the functional information 
obtained by 68Gallium-SSTR-PET alone (without a CT image) was notconsidered specific enough to 
suggestsurgery. 
Many treatment options are available for the medical management of the EAS [3, 9] and, among them, 
steroidogenesis inhibitors are often used for the treatment of an occult EAS. In our patient, one of the 
most currently used drugs (ketoconazole) was the first to be prescribed. A couple of months later it was 
discontinued because its inefficacy and targeted therapy with a somatostatin analog was initiated, on the 
basis of the positive result with octreotide challenge test [2, 5]. Escape to treatment,after a long-standing 
effective therapy,may be observed because the long-term use of somatostatin analogs may alter 
expression of surface receptors in tumor cells; in such cases, it may be helpful to increase the analog dose 
(until the highest recommended dose is reached) or to change the therapeutic approach [2, 3, 15]. 
Although few studies exist on the use of pasireotide for the management of neuroendocrine tumors [16-
18], its off-label use was suggestedby the good biochemical control of hypercortisolism obtained with 
thesomatostatin analogfor several years. After a treatment with pasireotide 0,6 mg sc twice daily, a 
normalization of 24-h urinary free cortisol levels was obtained, before the surgical removal of the 
tumour. A study to evaluate the efficacy of pasireotide twice daily for normalizing 24-h urinary free 
cortisol in patients with EAS is ongoing and will be completed in December 2018 [19].   
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